Fig. 3.

Probabilistic sensitivity analysis for cholesterol and triglyceride lowering treatment strategies in combination with statin displayed on a cost-effectiveness plane. Results are visualized for primary (A) and secondary cardiovascular prevention (B). All costs are presented in Euros (€) and were inflation adjusted to 2021 values. The figure displays 1,000 iterations of the conducted probabilistic sensitivity analysis which simultaneously varies input parameters by their confidence intervals and defined distribution presented in Table 1. Treatment options were categorized in cholesterol lowering (ezetimibe, alirocumab, evolocumab) and triglyceride lowering (icosapent ethyl, fibrate) strategies based on the European Society of Cardiology guidelines [8]. QALYs and costs are displayed per person. QALY quality-adjusted life year